

Study Of P-selectin Glycoprotein Ligand 1 (PSGL-1) And Soluble P-selectin In Chronic Liver Disease And Their Correlation With Bleeding Or Thrombosis

THESIS

**Submitted In Partial Fulfillment For Master Degree
In Clinical And Chemical Pathology**

By

Rabab Fouad Mohamed Yassin

Under Supervision Of

Prof. Dr. Hoda Sadek

**Professor Of Clinical And Chemical Pathology
Faculty Of Medicine-Cairo University**

Prof. Dr. Bothaina Madkour

**Professor Researcher Of Haematology
Theodor Bilharz Research Institute**

Dr. Eman Abd El-Mohsen

**Lecturer Of Clinical And Chemical Pathology
Faculty Of Medicine-Cairo University**

2008

ABSTRACT

Bleeding and thrombotic complications are common problems in patients with chronic liver disease. P-selectin is platelet activation marker that has been shown to be involved in thrombogenesis as well as bleeding disorders and may represent a possible link between inflammation and thrombosis through its adhesion to P-selectin glycoprotein ligand-1 (PSGL-1, CD162) on leukocytes. PSGL-1 is a disulfide-bonded homodimeric mucin-like glycoprotein on leukocytes that interacts with P-, L-, and E-selectin. Thrombomodulin is a transmembrane endothelial receptor involved in protein C pathway and may play a role in regulation of coagulation and inflammation processes. In order to investigate the clinical and pathogenic role of sP-selectin, CD162 and serum thrombomodulin in chronic liver disease, they were measured in 35 patients with chronic liver disease divided into; portal vein thrombosis group (PVT)(n=14), hematemesis group (n=11) and conservative treatment group (n=10). sP-selectin was significantly elevated in all patient groups as a part of inflammatory and immunological reactions that take place in patients with chronic liver disease. However among the 3 studied groups, the patients with hematemesis showed the highest elevation, may be due to hyperactivity of platelets, while in the PVT the lowest increase in sP-selectin level was recorded. This could be due to consumption of sP-selectin during clot formation. However, decrease surface expression of CD162 on neutrophils was detected in all our studied groups; this may be due to leukocyte activation and endotoxemia occurring in chronic liver disease. Thrombomodulin was significantly elevated in all patient groups and portal PVT showed the highest increase due to its hypersecretion from the activated endothelium with thrombus

formation. However, marked elevation of thrombomodulin in patients with chronic liver disease could be one of hepatoma markers.

Key wards:

sP-selectin, thrombomodulin, P-selectin glycoprotein ligand-1 (PSGL-1, CD162), chronic liver disease, portal vein thrombosis, hematemesis and hepatocellular carcinoma.

ACKNOWLEDGEMENT

**"All the Praises and Thanks be to Allah,
The Lord of the Alamin"**

I wish to express my deepest gratitude to **Professor Dr. Hoda Sadeek**, Professor of Clinical Pathology, Faculty of Medicine, Cairo University, for her effective guidance, valuable suggestions, unlimited help and unfailing support.

I wish to express my deep appreciation and profound gratitude to **Professor Dr. Bothaena Madkour**, professor of Hematology, Theodor Bilharz Research Institute, for her indispensable guidance, instructive supervision, and continuous support since the very beginning of this research work.

I would like to extend my thanks to **Professor Dr. Salwa Toeima**, Professor of Haematology and Head of Hematology Theodor Bilharz Research Institute, for providing all the facilities possible for the success of this work.

I am greatly honored to express my sincere gratitude and deep appreciation to **Dr. Eman Abd-El Moheesn**, lecturer of Clinical Pathology, Faculty of Medicine, Cairo University for her gracious help and support.

I would like to extend my thanks to **DR. Abia Fouad** lecturer of Haematology, Theodor Bilharz Research Institute, for her help and support.

Many thanks go to my colleagues and the staff members of Hematology Department, Theodor Bilharz Research Institute, for their kind help and moral support.

I dedicate this work to my parents who have done and still doing a lot to me without waiting for anything in return and I hope I can pay even a small part of my debt to them.

Finally, I wish to thank my dear husband for his support, love and patience.

List of ABBREVIATIONS

Abbreviation	The full term
5-HT	5-hydroxytryptamine
ADP	Adenosine diphosphate
ADPase	Adenosine diphosphatase
AICF	Accelerated intravascular coagulation and fibrinolysis.
AIH	Autoimmune hepatitis
ALD	Autoimmune liver disease
ALT	Alanine aminotransferase.
AMA	Antimitochondrial antibodies
ANA	Anti nuclear reactivities
APC	Activated protein C
AST	Aspartate aminotransferase
AT III	Antithrombin III
BCS	Budd-Chiari syndrome
β -TG	Beta thromboglobulin
C4b	Complement system
Ca ⁺⁺	Calcium
c-AMP	Cyclic adenosine monophosphate
c DNA	Complementary deoxyribonucleic acid
CD	Cluster of differentiation
cGMP	Cyclic guanosine monophosphate
COX-1	Cyclooxygenase-1
CR	Consensus repeat
CTL	Cytotoxic T lymphocyte
DIC	Disseminated intravascular coagulation
EDRF	Endothelial derived relaxing factor
EGF	Epidermal growth factor
ECs	Endothelial cells
ENA-78	Extractable nuclear antigen-78
EPCR	Endothelial cell protein C receptor
ERK	Extracellular signal-regulated kinase
F1+2	Fragments 1+2
Fmlp	N-formyl-methionyl-leucyl-phenylalanine
FucT-VII	Fucosyltransferase enzyme
GAG	Glycosaminoglycans
gla	γ -carboxyglutamic acid
GlyCAM-1	Glycosylation-dependent cell adhesion molecule 1
GP	Glycoprotein
Hb	Hemoglobin concentration.
HBV	Hepatitis B virus

HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HMWK	High-molecular-weight kininogen
HPC	Hematopoietic progenitor cells
HRG	Histidine-rich glycoprotein
ICAM-1	Intercellular adhesion molecule-1
LC1	Liver cytosol type 1
LFA- 1	Leukocyte function-associated antigen-1
LKM1	Liver kidney microsomal antibody type 1
IL	Interleukin
LPS	Lipopolysaccharide
Ma	Maximum amplitude
Mac-1	Leukocyte integrin alpha M beta2
MAPK	Mitogen activated protein kinases
MOH	The Egyptian Ministry of Health
mRNA	Messenger ribonucleic acid
NF-Kb	Nuclear Factor κ B
NO	Nitric oxide gas
OCS	Open Canalicular System
PAF	Platelet activating factor
PAI-1	Plasminogen activator inhibitor-1
PAIg	Platelet- associated immunoglobulin
p-ANCA	Anticytoplasmic neutrophil antibodies with perinuclear pattern
PAR1	protease-activated receptor-1
PC	Protein C
PF3	Platelet factor 3
PF4	Platelet factor 4
PFA-100	Platelet function assay
PGI ₂	Prostaglandin
PIVKA	Proteins Induced by Vitamin K Absence
PMA	Phorbol 12-myristate acetate
PS	Protein S
PSC	Primary sclerosing cholangitis
PSGL-1	P-selectin glycoprotein ligand 1
PT	Prothrombin time
PTT	Partial thromboplastin time
PVT	Portal vein thrombosis
RANTES	Regulated upon activation normal T cell expressed presumed secreted
RBCs	Red blood cells.
scu-PA	Single-chain urokinase-type plasminogen activator
SERPINS	Serine protease inhibitors
SMA	Anti smooth muscle antibodies

TAFI	Thrombin-activatable fibrinolysis inhibitor
TAT	Thrombin-antithrombin III complex
TBRI	Theodor Bilharz Research Institute
tcu-PA/T	Thrombin-cleaved 2-chain urokinase-type plasminogen activator
tPA	Tissue plasminogen activator
TEG	Thromboelastography
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
Th1	T helper 1
Th2	T helper 2
TIPS	Transjugular intrahepatic portosystemic shunt
TM	Thrombomodulin
TMLeD/LeD	Lack the N-terminal lectin-like domain of TM
TNF- α	Tumor necrosis factor- α
Tpa	Tissue plasminogen activator
TPO	Thrombopoietin
TT	Thrombin time
TXA2	Thromboxane A2
VEGF	Vascular endothelial growth factor
VLA-4	Very late activation-4
vWF	von Willebrand Factor
WBCs	White blood cells

LIST OF CONTENTS

	PAGE
INTRODUCTION AND AIM OF THE WORK	1
REVIEW OF LITRETURE:	
CHAPTER 1	
An overview of hemostasis	3
CHAPTER 2	
P-selectin and its ligand P-selectin glycoprotein ligand 1(PSGL-1, CD162)	24
CHAPTER 3	
Thrombomodulin	45
CHAPTER 4	
Haemostatic abnormalities in patients with chronic liver diseases	59
PATIENTS AND METHODS	79
RESULTS	100
DISCUSSION	140
SUMMARY AND CONCLUSION	161
RECOMMENDATIONS	164
ARABIC SUMMARY	166
REFERENCES	168
APPENDIX	192

LIST OF FIGURES

	PAGE
Figure(1): Blood vessel architecture and functions in haemostasis.....	6
Figure(2): Events leading to haemostasis by formation of haemostatic plug.....	10
Figure(3): The clotting cascade.....	15
Figure(4): Fibrinolysis.....	23
Figure(5): Structure of selectins.....	25
Figure(6): Cell– cell interactions mediated by P-selectin and PSGL-1.....	32
Figure(7): Interactions between selectins and their counter-receptors.....	33
Figure(8): Model of the role of PSGL-1 and P-selectin in the recruitment of blood borne tissue factor and for fibrin generation in thrombi.....	37
Figure(9): Interplay of inflammation and hemostasis.....	41
Figure(10): Structure of thrombomodulin (TM) and activation of protein C (PC) and thrombin activatable fibrinolysis inhibitor (TAFI).....	46
Figure(11): Vasculoprotective effects of TM-PC-EPCR in response to injury.....	58
Figure(12): principles of ELIZA test.....	68
Figure(13): Standard curve of P-selectin.....	91
Figure(14): Standard curve of thrombomodulin.....	98

Figure(15): Mean value of CD 162 expression on neutrophils (%) in different studied groups.....	126
Figure(16): Mean value of serum P-selectin (ng/ml) in different studied groups.....	127
Figure(17): Mean value of serum thrombomodulin (ng/ml) in different studied groups.....	128
Figure(18): Percent (%) of HCV Ab and HBs Ag positive patients in all studied groups.....	129
Figure(19): Percent (%) of HCV Ab positive patients in different studied groups.....	130
Figure(20): Correlation between platelets count and P-selectin in all patient included in the study.....	131
Figure(21): Correlation between platelets count and P-selectin in portal vein thrombosis group included in the study.....	132
Figure(22): Correlation between platelets count and P-selectin in hematemesis group included in the study.....	133
Figure(23): Correlation between prothrombin time and serum p-selectin in conservative treatment group included in the study.....	134
Figure(24): Correlation between prothrombin time and thrombomodulin in all patient included in the study.....	135
Figure(25): Correlation between prothrombin time and thrombomodulin in hematemesis group included in the study.....	136
Figure(26): Correlation between prothrombin time and serum albumin in all patient groups included in the study.....	137

LIST OF TABLES

	PAGE
Table(1): Coagulation factors and their function	12
Table(2): Regulatory protein.....	18
Table(3): Hemostatic abnormalities associated with liver disease.....	63
Table(4): Reagents provided in sCD62 ELIZA kit.....	87
Table(5): Summary of assay procedure sCD62 ELIZA kit.....	90
Table(6): Reagents provided in CD141 ELISA kit.....	92
Table(7): Dilution of Biotinylated anti-CD141 detection antibody and Streptavidin-HRP of thrombomodulin ELIZA kit.....	94
Table(8): Summary of assay procedure of CD141 ELISA kit.....	97
Table(9): Descriptive statistics of hematological data of controls included in the study.....	102
Table(10): Descriptive statistics of chemistry data of controls included in the study.....	102
Table(11): Descriptive statistics of special investigations of controls included in the study.....	102
Table(12): Comparison between demographic data of patients with portal vein thrombosis, hematemesis and conservative treatment included in the study.....	104
Table(13): Descriptive statistics of hematological data of all patients included in the study.....	106
Table(14): Descriptive statistics of chemistry data of all patients included in the study.....	106
Table(15): Descriptive statistics of special investigations of all patients included in the study.....	107

Table(16): Descriptive statistics of hematological data of patients with portal vein thrombosis included in the study.....	109
Table(17): Descriptive statistics of chemistry data of patients with portal vein thrombosis included in the study.....	109
Table(18): Descriptive statistics of special investigations of patients with portal vein thrombosis included in the study.....	110
Table(19): Descriptive statistics of hematological data of patients with hematemesis included in the study.....	112
Table(20): Descriptive statistics of chemistry data of patients with hematemesis included in the study.....	112
Table(21): Descriptive statistics of special investigations of patients with hematemesis included in the study.....	112
Table(22): Descriptive statistics of hematological data of patients with conservative treatment included in the study.....	115
Table(23): Descriptive statistics of chemistry data of patients with conservative treatment included in the study.....	115
Table(24): Descriptive statistics of special investigations of patients with conservative treatment included in the study.....	115
Table(25): Comparison between hematological data of all patients included in the study and controls.....	116
Table(26): Comparison between chemistry data of all patients included in the study and controls	117
Table(27): Comparison between special investigations of all patients included in the study and controls	117